Member Info for Onetomany

With the abundance of time you seem to have on your hands, why don’t you do some research and try calculate their expenditure since April. I am telling, they have a healthy cash position now and the revised lender terms will be more attractive. Once they decide to do the work over (I think this is already in process) then you may see 10/20/30% increase. Bear in mind revenue has tripled from Q2 and more than double the previous highs.

Like I said, game changing.

the extract below from the first of the two completely pointless rns’s has ever concerning wording. firstly they talk about discussions in the present and future tenses. this is new information, contrary to the fake interviews that spouted past tense and the sped at which the big pharmas came back to the table (that was 2 months ago). secondly there is ‘stated objective’ of a deal (singular). much less ****y is tim and we have reverted to deal, rather than deals. all in all, i am skeptical if there ever will be a deal, it doesn’t seem likely imo.

the company is engaging with a number of potential partners. the company has a comprehensive data room which all potential partners, on the signing of a confidential disclosure agreement, have the opportunity to access the most recent data and clinical findings, in order to carry out the appropriate due diligence necessary.

further updates, as appropriate, will be communicated to the market between now and our stated objective of completing a deal by the end of 2025.

What has changed is the dramatic increase in revenue. This is a complete game changer and you will see a substantial rerating upon re-listing.

They’re not in default and they haven’t consumed anywhere near £16m so that cash position will be strong. Revenue has tripled in recent months, not bad eh?

You think they’ve consumed £16m?

It’s not a real closing price. It is the final trade of the day. LSE never shows the correct share price for some reason, we know what a mid price is and that this the price.

Shut up, no it’s not. Try post something meaningful next time.

11 now and not much support down to 10.55

Bid dropped back dramatically. Weird action

Bid should move up shortly. More strengthening. Looks like today could be the start of the run up, referenced by chartists.

In the last 30 mins. Something happening.

Seems to be consistent and solid now. Look forward to seeing their cash position, must be significant now. October revenue in excess of whole of Q2,

Hopefully the patent will be approved some time 2027. Anyone have an idea if it could be done in less than 24 months?

Something not right, I’m sure to be revealed soon.

Market doesn’t like it. More to come sadly. I think poor communication is at the core. Too much ambiguity and some feel mislead.

Alan your valuable feedback is always welcome, the whole board appreciated your contributions. Maybe I’m just too cynical, but I do wonder why all the hype on here hasn’t translated in to any market interest and the share price languishes (based on the mean dreamer level).

With cash and assets at a fraction of mcap, do you think a full mega deal is already priced in ?

Interested in the avion comments, some folk seem to be in the know on that. It seems.

Very tough times. The market really not liking what IMM have / are doing. Market usually not wrong but let’s see. The elephant in the room is a big one it seems.

He won’t address the elephant in the room publicly.

Yes another game changer. These guys really are pathetic

Higher than whole of Q2. Transformational period right now, financially. There must be some cash pile sitting.